Overview
CATX market data
Price History
CATX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.40 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.81 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -17,982.7% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.96 – $6.16 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $342.1M · P/B 0.99 · P/S 553.62.
Company News
B of A Securities Maintains Neutral on Perspective Therapeutics, Lowers Price Target to $5Benzinga · Aug 14, 2026, 6:18 PM
Perspective Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS results.Benzinga · Aug 11, 2026, 7:53 PM
Piper Sandler Maintains Overweight on Perspective Therapeutics, Lowers Price Target to $14Benzinga · Aug 11, 2026, 1:14 PM
Perspective Therapeutics Q2 EPS $(0.22) Beats $(0.26) Estimate, Sales $81.000K Miss $83.154K EstimateBenzinga · Aug 10, 2026, 8:41 PM
8-K filing — Perspective Therapeutics, Inc. (CATX)SEC EDGAR · Aug 10, 2026, 8:30 PM
Perspective Therapeutics Receives European Commission Orphan Designation For VMT-α-NET To Treat Gastroenteropancreatic Neuroendocrine TumorsBenzinga · Jul 28, 2026, 10:42 AM
Perspective Therapeutics' Updated Data On Its [212Pb]VMT-α-NET Program Accepted For Presentation At European Society Of Medical Oncology Congress 2026Benzinga · Jul 17, 2026, 4:24 PM
Ericsson, Q32 Bio And Other Big Stocks Moving Lower In Tuesday’s Pre-Market SessionBenzinga · Jul 14, 2026, 12:03 PM
Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in MelanomaGlobenewswire Inc · May 21, 2026, 10:15 PM
Perspective Therapeutics Reports Early Response SignalS And Favorable Safety Across Three Radiopharmaceutical Programs At ASCO 2026, Including 29% Response Rate In Advanced Melanoma CohortBenzinga · May 21, 2026, 10:00 PM